Clinical Research Directory
Browse clinical research sites, groups, and studies.
EMpagliflozin to PREvent worSening of Left Ventricular Volumes and Systolic Function After Myocardial Infarction
Sponsor: NHS Greater Glasgow and Clyde
Summary
The addition of the SGLT2 inhibitor empagliflozin 10mg once daily to standard-of-care therapy administered early following acute myocardial infarction will result in a greater attenuation of adverse left ventricular remodelling, compared with matched placebo, in patients with left ventricular systolic dysfunction as a result of an acute myocardial infarction.
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
100
Start Date
2022-09-16
Completion Date
2024-06-12
Last Updated
2024-04-02
Healthy Volunteers
No
Conditions
Interventions
Empagliflozin 10 MG
SGLT2inhibitor
Placebo
Matched placebo
Locations (3)
Glasgow Royal Infirmary
Glasgow, Strathclyde, United Kingdom
Golden Jubilee National Hospital
Glasgow, United Kingdom
NHS Greater Glasgow and Clyde
Glasgow, United Kingdom